AstraZeneca Sees Further Growth, Lifted by Cancer Drugs

AstraZeneca Plc expects profit to grow further this year, boosted by sales of its cancer drugs as it works to offset a patent expiry of a blockbuster diabetes medicine.

Earnings per share, excluding some items, are expected to rise by a low double-digit percentage, the UK drugmaker said Tuesday. That’s in line with what analysts anticipated. Astra also reported fourth-quarter profit and revenue that roughly met estimates.